380 related articles for article (PubMed ID: 31926332)
21. Cathepsins and cystatin C in atherosclerosis and obesity.
Lafarge JC; Naour N; Clément K; Guerre-Millo M
Biochimie; 2010 Nov; 92(11):1580-6. PubMed ID: 20417681
[TBL] [Abstract][Full Text] [Related]
22. Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.
De Pasquale V; Moles A; Pavone LM
Cells; 2020 Apr; 9(4):. PubMed ID: 32326609
[TBL] [Abstract][Full Text] [Related]
23. Overview of multifunctional cysteinyl cathepsins in atherosclerosis-based cardiovascular disease: from insights into molecular functions to clinical implications.
Cheng XW; Narisawa M; Wang H; Piao L
Cell Biosci; 2023 May; 13(1):91. PubMed ID: 37202785
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo.
Quillard T; Croce K; Jaffer FA; Weissleder R; Libby P
Thromb Haemost; 2011 May; 105(5):828-36. PubMed ID: 21225096
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells.
Liu J; Sukhova GK; Yang JT; Sun J; Ma L; Ren A; Xu WH; Fu H; Dolganov GM; Hu C; Libby P; Shi GP
Atherosclerosis; 2006 Feb; 184(2):302-11. PubMed ID: 15982660
[TBL] [Abstract][Full Text] [Related]
26. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms.
Swedenborg J; Mäyränpää MI; Kovanen PT
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):734-40. PubMed ID: 21205988
[TBL] [Abstract][Full Text] [Related]
27. Activity and localization of cathepsin B, D and G in aortic aneurysm.
Gacko M; Chyczewski L
Int Surg; 1997; 82(4):398-402. PubMed ID: 9412840
[TBL] [Abstract][Full Text] [Related]
28. Differential hypertensive protease expression in the thoracic versus abdominal aorta.
Ruddy JM; Akerman AW; Kimbrough D; Nadeau EK; Stroud RE; Mukherjee R; Ikonomidis JS; Jones JA
J Vasc Surg; 2017 Nov; 66(5):1543-1552. PubMed ID: 28034583
[TBL] [Abstract][Full Text] [Related]
29. Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis.
Platt MO; Ankeny RF; Shi GP; Weiss D; Vega JD; Taylor WR; Jo H
Am J Physiol Heart Circ Physiol; 2007 Mar; 292(3):H1479-86. PubMed ID: 17098827
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological Inhibition of Cathepsin S Suppresses Abdominal Aortic Aneurysm in Mice.
Lai CH; Chang JY; Wang KC; Lee FT; Wu HL; Cheng TL
Eur J Vasc Endovasc Surg; 2020 Jun; 59(6):990-999. PubMed ID: 32033870
[TBL] [Abstract][Full Text] [Related]
31. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.
Hua Y; Nair S
Biochim Biophys Acta; 2015 Feb; 1852(2):195-208. PubMed ID: 24815358
[TBL] [Abstract][Full Text] [Related]
32. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis.
Li W; Yuan XM
Ann N Y Acad Sci; 2004 Dec; 1030():427-33. PubMed ID: 15659826
[TBL] [Abstract][Full Text] [Related]
33. Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor.
Ahmad S; Siddiqi MI
J Mol Model; 2017 Mar; 23(3):92. PubMed ID: 28236030
[TBL] [Abstract][Full Text] [Related]
34. A Theranostic Cathepsin Activity-Based Probe for Noninvasive Intervention in Cardiovascular Diseases.
Weiss-Sadan T; Ben-Nun Y; Maimoun D; Merquiol E; Abd-Elrahman I; Gotsman I; Blum G
Theranostics; 2019; 9(20):5731-5738. PubMed ID: 31534515
[TBL] [Abstract][Full Text] [Related]
35. Lysosomal cysteine cathepsins: signaling pathways in apoptosis.
Stoka V; Turk V; Turk B
Biol Chem; 2007 Jun; 388(6):555-60. PubMed ID: 17552902
[TBL] [Abstract][Full Text] [Related]
36. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis.
de Nooijer R; Bot I; von der Thüsen JH; Leeuwenburgh MA; Overkleeft HS; Kraaijeveld AO; Dorland R; van Santbrink PJ; van Heiningen SH; Westra MM; Kovanen PT; Jukema JW; van der Wall EE; van Berkel TJ; Shi GP; Biessen EA
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):188-94. PubMed ID: 19095996
[TBL] [Abstract][Full Text] [Related]
37. Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.
Brix K; McInnes J; Al-Hashimi A; Rehders M; Tamhane T; Haugen MH
Protoplasma; 2015 May; 252(3):755-74. PubMed ID: 25398648
[TBL] [Abstract][Full Text] [Related]
38. Role of Myeloperoxidase Oxidants in the Modulation of Cellular Lysosomal Enzyme Function: A Contributing Factor to Macrophage Dysfunction in Atherosclerosis?
Ismael FO; Barrett TJ; Sheipouri D; Brown BE; Davies MJ; Hawkins CL
PLoS One; 2016; 11(12):e0168844. PubMed ID: 27997605
[TBL] [Abstract][Full Text] [Related]
39. Mesangial cell hypertrophy induced by NH4Cl: role of depressed activities of cathepsins due to elevated lysosomal pH.
Ling H; Ardjomand P; Samvakas S; Simm A; Busch GL; Lang F; Sebekova K; Heidland A
Kidney Int; 1998 Jun; 53(6):1706-12. PubMed ID: 9607203
[TBL] [Abstract][Full Text] [Related]
40. The role of lysosomal cysteine cathepsins in NLRP3 inflammasome activation.
Campden RI; Zhang Y
Arch Biochem Biophys; 2019 Jul; 670():32-42. PubMed ID: 30807742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
